updated analysis from mountaineer: tucatinib and trastuzumab for her2-positive mcrc
Published 2 years ago • 118 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:11
32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
0:56
mountaineer results: trastuzumab and tucatinib for her2 mcrc
-
0:36
tucatinib & trastuzumab /- chemo or pembrolizumab in unresectable or metastatic her2 gi cancers
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
2:33
her2climb: tucatinib with trastuzumab and capecitabine for her2 breast cancer with brain metastases
-
1:12
her2climb-04: tucatinib trastuzumab deruxtecan in her2 breast cancer
-
0:52
the significance of tucatinib trastuzumab as a chemotherapy-free option for her2 metastatic btc
-
1:11
her2climb: tucatinib efficacious against brain metastases in patients with her2 breast cancer
-
1:47
her2climb-05: tucatinib trastuzumab and pertuzumab as maintenance therapy for her2 metastatic bc
-
1:46
choosing between tucatinib and t-dxd in her2 breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
1:30
tucatinib in her2 breast cancer with leptomeningeal metastases
-
2:28
mountaineer: impact of genomic alterations on tucatinib plus trastuzumab activity in mcrc
-
4:46
mountaineer: tucatinib in combination with trastuzumab for her2-positive metastatic colorectal c...
-
3:15
her2climb-02: tucatinib tdm-1 in advanced breast cancer
-
0:58
mountaineer: clinical relevance of genomic profiling for tucatinib trastuzumab treatment in mcrc
-
1:42
dr. bekaii-saab on the rationale to explore tucatinib/trastuzumab in her2-overexpressing mcrc
-
1:08
targeting her2 in colorectal cancer